Clinical Trial Results:
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a
Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma.
Revised Protocol 03, incorporating Protocol Amendment 04 (V1.0, Date 26-Aug-2008), Protocol Amendment 05 (V1.0, Date 20-Nov-2008), and Protocol Amendment 06 (V1.0, date 05-Jan-2009).
+ Protocol Amendment 07, country specific - Germany (V1.0, date 19-Dec-2008).
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (V1.0, Date 26-Nov-2007).
Summary
|
|
EudraCT number |
2007-003993-24 |
Trial protocol |
DE FR IT DK |
Global completion date |
12 Oct 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA186-006_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.